{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T14:33:59Z","timestamp":1775313239773,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Platelet glycoprotein VI (GPVI) receptor is essential for platelet adhesion and aggregation. Eltrombopag is as an effective treatment for chronic immune thrombocytopenia (ITP); yet, its effect on platelet function is not fully characterized.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>This prospective study investigated the effect of eltrombopag therapy on platelet function through assessment of GPVI receptor expression and soluble GPVI levels among pediatric patients with persistent or chronic ITP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Thirty-six children and adolescents with persistent or chronic ITP were divided equally into two groups either to receive eltrombopag therapy or the standard of care. All patients were followed-up for 12 months with assessment of bleeding score and complete blood count (CBC). Evaluation of GPVI expression using flow cytometry and measurement of its soluble form by ELISA was done at baseline and at 6 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ITP patients on eltrombopag had significantly lower bleeding score after 6 months of therapy while the quality of life has significantly improved. Platelet count was significantly increased throughout the study. GPVI expression by flow cytometry and soluble GPVI levels were significantly increased after eltrombopag therapy. After 12 months, ITP patients on eltrombopag were able to maintain a good quality of life and low bleeding score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our data suggest that eltrombopag, through its effect on the GPVI receptor expression and its soluble form, might reduce bleeding manifestations and improve the quality of life of chronic and persistent ITP children independent of its effect on the platelet count.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11239-022-02734-1","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T09:08:51Z","timestamp":1670404131000},"page":"243-251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia"],"prefix":"10.1007","volume":"55","author":[{"given":"Azza Abdel Gawad","family":"Tantawy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7249-7971","authenticated-orcid":false,"given":"Nayera Hazaa Khalil","family":"Elsherif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma Soliman","family":"Ebeid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha Abd El-Rahman","family":"El-Gamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman Abdel Rahman","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud A.","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Botros Elkes","family":"morcos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"2734_CR1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.21833","volume":"85","author":"DR Terrell","year":"2010","unstructured":"Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN (2010) The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 85:174\u2013180","journal-title":"Am J Hematol"},{"key":"2734_CR2","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1056\/NEJMra010501","volume":"346","author":"DB Cines","year":"2002","unstructured":"Cines DB, Blanchette VS (2002) Immune thrombocytopenic purpura. N Engl J Med 346:995\u20131008","journal-title":"N Engl J Med"},{"key":"2734_CR3","doi-asserted-by":"crossref","unstructured":"Kohli R, Chaturvedi S (2019); 39:238\u2013249","DOI":"10.1055\/s-0039-1683416"},{"key":"2734_CR4","first-page":"e9920","volume":"12","author":"E Bidika","year":"2020","unstructured":"Bidika E, Fayyaz H, Salib M, Memon AN, Gowda AS, Rallabhandi B, Cancarevic I (2020) Romiplostim and Eltrombopag in Immune Thrombocytopenia as a second-line treatment. Cureus 12:e9920","journal-title":"Cureus"},{"key":"2734_CR5","first-page":"CS100","volume":"16","author":"J Meletis","year":"2010","unstructured":"Meletis J, Katsandris A, Raptis SD, Mantzourani M (2010) Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim. Med Sci Monit 16:CS100\u2013CS102","journal-title":"Med Sci Monit"},{"key":"2734_CR6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/bloodadvances.2017010660","volume":"2","author":"TO Kim","year":"2018","unstructured":"Kim TO, Despotovic J, Lambert MP (2018) Eltrombopag for use in children with immune thrombocytopenia. Blood Adv 2:454\u2013461","journal-title":"Blood Adv"},{"key":"2734_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/2042098618769587","volume":"9","author":"JR Gonzalez-Porras","year":"2018","unstructured":"Gonzalez-Porras JR, Bastida JM (2018) Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. Ther Adv Drug Saf 9:263\u2013285","journal-title":"Ther Adv Drug Saf"},{"key":"2734_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1600-0609.2007.00900.x","volume":"79","author":"S Panzer","year":"2007","unstructured":"Panzer S, Hocker L, Rieger M, Vormittag R, Koren D, Dunkler D, Pabinger I (2007) Agonist-inducible platelet activation in chronic idiopathic autoimmune thrombocytopenia. Eur J Haematol 79:198\u2013204","journal-title":"Eur J Haematol"},{"key":"2734_CR9","first-page":"241","volume":"35","author":"LA Harker","year":"1998","unstructured":"Harker LA (1998) Platelets in thrombotic disorders: quantitative and qualitative platelet disorders predisposing to arterial thrombosis. Semin Hematol 35:241\u2013252","journal-title":"Semin Hematol"},{"key":"2734_CR10","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1182\/blood-2011-11-393900","volume":"119","author":"B Psaila","year":"2012","unstructured":"Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, Tate C, Mathur K, Frelinger AL, Michelson AD (2012) In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood 119:4066\u20134072","journal-title":"Blood"},{"key":"2734_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.tmrv.2014.03.001","volume":"28","author":"EE Gardiner","year":"2014","unstructured":"Gardiner EE, Andrews RK (2014) Platelet receptor expression and shedding: glycoprotein Ib-IX-V and glycoprotein VI. Trans Med Rev 28:56\u201360","journal-title":"Trans Med Rev"},{"key":"2734_CR12","doi-asserted-by":"crossref","unstructured":"Yun SH, Sim EH, Goh RY, Park JI, Han JY (2016) Platelet activation: the Mechanisms and potential biomarkers. BioMed Res Int; 1\u20135","DOI":"10.1155\/2016\/9060143"},{"key":"2734_CR13","doi-asserted-by":"publisher","first-page":"48333","DOI":"10.1074\/jbc.M206127200","volume":"277","author":"ML Holmes","year":"2002","unstructured":"Holmes ML, Bartle N, Eisbacher M, Chong BH (2002) Cloning and analysis of the thrombopoietin-induced megakaryocyte-specific glycoprotein VI promoter and its regulation by GATA-1, Fli-1, and Sp1. J Biol Chem 277:48333\u201348341","journal-title":"J Biol Chem"},{"key":"2734_CR14","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1182\/blood-2004-08-3109","volume":"105","author":"S Kanaji","year":"2005","unstructured":"Kanaji S, Kanaji T, Jacquelin B, Chang M, Nugent DJ, Komatsu N, Moroi M, Izuhara K, Kunicki TJ (2005) Thrombopoietin initiates demethylation-based transcription of GP6 during megakaryocyte differentiation. Blood 105:3888\u20133892","journal-title":"Blood"},{"key":"2734_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.exphem.2004.09.006","volume":"33","author":"CL Erickson-Miller","year":"2005","unstructured":"Erickson-Miller CL, DeLorme E, Tian SS, Hopson CB, Stark K, Giampa L, Valoret EI, Duffy KJ, Luengo JL, Rosen J, Miller SG (2005) Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 33:85\u201393","journal-title":"Exp Hematol"},{"key":"2734_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2141.2007.06635.x","volume":"138","author":"LK Page","year":"2007","unstructured":"Page LK, Psaila B, Provan D, Michael Hamilton J, Jenkins JM, Elish AS, Lesser ML, Bussel JB (2007) The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br J Haematol 138:245\u2013248","journal-title":"Br J Haematol"},{"key":"2734_CR17","doi-asserted-by":"publisher","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","volume":"152","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152:726\u2013732","journal-title":"Ann Intern Med"},{"issue":"9664","key":"2734_CR18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","volume":"373","author":"JB Bussel","year":"2009","unstructured":"Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N (2009) Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 373(9664):641\u2013648","journal-title":"Lancet"},{"key":"2734_CR19","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386\u20132393","journal-title":"Blood"},{"key":"2734_CR20","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, K\u00fchne T (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3:3829\u20133866","journal-title":"Blood Adv"},{"key":"2734_CR21","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","volume":"2","author":"JB Bussel","year":"2015","unstructured":"Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK (2015) Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2:e315\u2013e257","journal-title":"Lancet Haematol"},{"key":"2734_CR22","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1182\/blood.V126.23.1054.1054","volume":"126","author":"JB Bussel","year":"2015","unstructured":"Bussel JB, Mahmud SN, Brigstocke SL, Torneten SM (2015) Tapering eltrombopag in patients with chronic ITP: how successful is this and in whom does it work? Blood 126:1054","journal-title":"Blood"},{"key":"2734_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jpeds.2007.01.037","volume":"150","author":"RJ Klaassen","year":"2007","unstructured":"Klaassen RJ, Blanchette VS, Barnard D, Wakefield CD, Curtis C, Bradley CS, Neufeld EJ, Buchanan GR, Silva MP, Chan AK, Young NL (2007) Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids\u2019 ITP Tools. J Pediatr 150:510\u2013515","journal-title":"J Pediatr"},{"key":"2734_CR24","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1093\/eurheartj\/ehl192","volume":"27","author":"B Bigalke","year":"2006","unstructured":"Bigalke B, Lindemann S, Ehlers R, Seizer P, Daub K, Langer H, Schonberger T, Kremmer E, Siegel-Axel D, May AE, Gawaz M (2006) Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 27:2165\u20132169","journal-title":"Eur Heart J"},{"key":"2734_CR25","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1160\/TH08-06-0399","volume":"101","author":"B Bigalke","year":"2009","unstructured":"Bigalke B, Stellos K, Stakos D, Joos T, P\u00f6tz O, Geisler T, Bischofs C, Kremmer E, Kr\u00e4mer BF, Seizer P, May AE (2009) Influence of platelet count on the expression of platelet collagen receptor glycoprotein VI (GPVI) in patients with acute coronary syndrome. Thromb Haemost 101:911\u2013915","journal-title":"Thromb Haemost"},{"key":"2734_CR26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1096\/fj.03-0464fje","volume":"18","author":"S Massberg","year":"2004","unstructured":"Massberg S, Konrad I, B\u00fcltmann A, Schulz C, M\u00fcnch G, Peluso M, Lorenz M, Schneider S, Besta F, M\u00fcller I, Hu B (2004) Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 18:397\u2013399","journal-title":"FASEB J"},{"key":"2734_CR27","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.jpsychires.2007.07.017","volume":"42","author":"C Laske","year":"2008","unstructured":"Laske C, Leyhe T, Stransky E, Eschweiler GW, Bueltmann A, Langer H, Stellos K, Gawaz M (2008) Association of platelet-derived soluble glycoprotein VI in plasma with Alzheimer\u2019s disease. J Psychiatr Res 42:746\u2013751","journal-title":"J Psychiatr Res"},{"key":"2734_CR28","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","volume":"386","author":"JD Grainger","year":"2015","unstructured":"Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK (2015) Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 386:1649\u20131658","journal-title":"Lancet"},{"key":"2734_CR29","first-page":"661","volume":"7","author":"P Giordano","year":"2020","unstructured":"Giordano P, Lassandro G, Barone A, Cesaro S, Fotzi I, Giona F, Ladogana S, Miano M, Marzollo A, Nardi M, Notarangelo LD (2020) Use of Eltrombopag in Children with Chronic Immune Thrombocytopenia (ITP): a Real Life Retrospective Multicenter experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Front Med (Lausanne) 7:661\u2013667","journal-title":"Front Med (Lausanne)"},{"key":"2734_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/16078454.2020.1856511","volume":"26","author":"M Chen","year":"2021","unstructured":"Chen M, Fang JP, Zhou CX, Li XY, Lin SF, Xu LH (2021) Efficacy and safety of eltrombopag in the treatment of chinese children with chronic immune thrombocytopenia. Hematol 26:31\u201336","journal-title":"Hematol"},{"key":"2734_CR31","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/17474086.2018.1548930","volume":"11","author":"HG Sest\u00f8l","year":"2018","unstructured":"Sest\u00f8l HG, Trangb\u00e6k SM, Bussel JB, Frederiksen H (2018) Health-related quality of life in adult primary immune thrombocytopenia. Expert Rev Hematol 11:975\u2013985","journal-title":"Expert Rev Hematol"},{"key":"2734_CR32","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ajh.25479","volume":"94","author":"RF Grace","year":"2019","unstructured":"Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM (2019) Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. Am J Hematol 94:741\u2013750","journal-title":"Am J Hematol"},{"key":"2734_CR33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/bjh.15732","volume":"185","author":"JD Grainger","year":"2019","unstructured":"Grainger JD, Blanchette VS, Grotzinger KM, Roy A, Bussel JB (2019) Health related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study. Br J Haematol 185:102\u2013106","journal-title":"Br J Haematol"},{"key":"2734_CR34","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/j.1538-7836.2008.03016.x","volume":"6","author":"EE Gardiner","year":"2008","unstructured":"Gardiner EE, Al-Tamimi M, Mu FT, Karunakaran D, Thom JY, Moroi M, Andrews RK, Berndt MC, Baker RI (2008) Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura. J Thromb Haemost 6:1175\u20131182","journal-title":"J Thromb Haemost"},{"key":"2734_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/09537100802710286","volume":"20","author":"M Al-Tamimi","year":"2009","unstructured":"Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK (2009) Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 20:143\u2013149","journal-title":"Platelets"},{"key":"2734_CR36","first-page":"59","volume":"5","author":"RK Andrews","year":"2014","unstructured":"Andrews RK, Arthur JF, Gardiner EE (2014) Targeting GPVI as a novel antithrombotic strategy. J Blood Med 5:59\u201368","journal-title":"J Blood Med"},{"key":"2734_CR37","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/blood-2004-03-0896","volume":"104","author":"B Boylan","year":"2004","unstructured":"Boylan B, Chen H, Rathore V, Paddock C, Salacz M, Friedman KD, Curtis BR, Stapleton M, Newman DK, Kahn ML, Newman PJ (2004) Anti- GPVI-associated ITP: an acquired platelet disorder caused by autoantibody- mediated clearance of the GPVI\/FcRc-chain complex from the human platelet surface. Blood 104:1350\u20131355","journal-title":"Blood"},{"key":"2734_CR38","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.trsl.2015.09.005","volume":"166","author":"TJ Chiou","year":"2015","unstructured":"Chiou TJ, Chang YF, Wang MC, Kao CW, Lin HY, Chen TY, Hsueh EJ, Lan YJ, Sung YC, Lin SF, Bai LY (2015) Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura. Transl Res 166:750\u2013776","journal-title":"Transl Res"},{"key":"2734_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00277-011-1249-5","volume":"91","author":"J Haselboeck","year":"2012","unstructured":"Haselboeck J, Pabinger I, Ay C, Koder S, Panzer S (2012) Platelet activation and function during eltrombopag treatment in immune thrombocytopenia. Ann Hematol 91:109\u2013113","journal-title":"Ann Hematol"},{"key":"2734_CR40","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1111\/bjh.16164","volume":"187","author":"AA Ignatova","year":"2019","unstructured":"Ignatova AA, Demina IA, Ryabykh AA, Obydennyi SI, Polokhov DM, Seregina EA, Poletaev AV, Ataullakhanov FI, Maschan AA, Novichkova GA, Panteleev MA (2019) Evolution of platelet function in adult patients with chronic immune thrombocytopenia on romiplostim treatment. Br J Haematol 187:e38\u201342","journal-title":"Br J Haematol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-022-02734-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-022-02734-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-022-02734-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T16:07:04Z","timestamp":1701533224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-022-02734-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["2734"],"URL":"https:\/\/doi.org\/10.1007\/s11239-022-02734-1","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,7]]},"assertion":[{"value":"17 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors do not have any conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosure"}}]}}